CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: rectal adenocarcinoma</title> <meta name="description" content="Search results for: rectal adenocarcinoma"> <meta name="keywords" content="rectal adenocarcinoma"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="rectal adenocarcinoma" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="rectal adenocarcinoma"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 146</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: rectal adenocarcinoma</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">146</span> Biomarkers for Rectal Adenocarcinoma Identified by Lipidomic and Bioinformatic</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Patricia%20O.%20Carvalho">Patricia O. Carvalho</a>, <a href="https://publications.waset.org/abstracts/search?q=Marcia%20C.%20F.%20Messias"> Marcia C. F. Messias</a>, <a href="https://publications.waset.org/abstracts/search?q=Laura%20Credidio"> Laura Credidio</a>, <a href="https://publications.waset.org/abstracts/search?q=Carlos%20A.%20R.%20Martinez"> Carlos A. R. Martinez</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Lipidomic strategy can provide important information regarding cancer pathogenesis mechanisms and could reveal new biomarkers to enable early diagnosis of rectal adenocarcinoma (RAC). This study set out to evaluate lipoperoxidation biomarkers, and lipidomic signature by gas chromatography (GC) and electrospray ionization-qToF-mass spectrometry (ESI-qToF-MS) combined with multivariate data analysis in plasma from 23 RAC patients (early- or advanced-stages cancer) and 18 healthy controls. The most abundant ions identified in the RAC patients were those of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) while those of lisophosphatidylcholine (LPC), identified as LPC (16:1), LPC (18:1) and LPC (18:2), were down-regulated. LPC plasmalogen containing palmitoleic acid (LPC (P-16:1)), with highest VIP score, showed a low tendency in the cancer patients. Malondialdehyde plasma levels were higher in patients with advanced cancer (III/IV stages) than in the early stages groups and the healthy group (p<0.05). No differences in F2-isoprostane levels were observed between these groups. This study shows that the reduction in plasma levels of LPC plasmalogens associated to an increase in MDA levels may indicate increased oxidative stress in these patients and identify the metabolite LPC (P-16:1) as new biomarkers for RAC. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biomarkers" title="biomarkers">biomarkers</a>, <a href="https://publications.waset.org/abstracts/search?q=lipidomic" title=" lipidomic"> lipidomic</a>, <a href="https://publications.waset.org/abstracts/search?q=plasmalogen" title=" plasmalogen"> plasmalogen</a>, <a href="https://publications.waset.org/abstracts/search?q=rectal%20adenocarcinoma" title=" rectal adenocarcinoma"> rectal adenocarcinoma</a> </p> <a href="https://publications.waset.org/abstracts/78907/biomarkers-for-rectal-adenocarcinoma-identified-by-lipidomic-and-bioinformatic" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/78907.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">230</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">145</span> A Case Report on the Multidisciplinary Approach on Rectal Adenocarcinoma in Pregnancy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Maria%20Cristina%20B.%20Cabanag">Maria Cristina B. Cabanag</a>, <a href="https://publications.waset.org/abstracts/search?q=Elijinese%20Marie%20S.%20Culangen"> Elijinese Marie S. Culangen</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Pregnancy is a period in a woman's life wherein the body may undergo different physiological changes. These changes can be attributed to the interplay of hormones in the body but can mask a more sinister type of disease such as malignancy on rare occasions. Colorectal cancer (CRC) in pregnancy is an epidemiologically rare disease worldwide. To our knowledge, no available studies were reported in the Philippines at the time of this writing, posing a dilemma for its appropriate diagnosis and management. Signs and symptoms of colorectal malignancy may camouflage a normal pregnancy and, when overlooked, impedes an appropriate approach. This case of a 38-year-old elderly primigravid who presented with hematochezia on her 25th week of gestation. She was diagnosed with rectal adenocarcinoma later in pregnancy which warranted a predicament regarding her appropriate care and management. This paper explores the repertoire of the different diagnostic and treatment approaches to colorectal cancer in the second trimester of pregnancy, with the least possible maternal and fetal hazards. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cancer%20in%20pregnancy" title="cancer in pregnancy">cancer in pregnancy</a>, <a href="https://publications.waset.org/abstracts/search?q=chemotherapy%20in%20pregnancy" title=" chemotherapy in pregnancy"> chemotherapy in pregnancy</a>, <a href="https://publications.waset.org/abstracts/search?q=colorectal%20cancer" title=" colorectal cancer"> colorectal cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=hematochezia%20in%20pregnancy" title=" hematochezia in pregnancy"> hematochezia in pregnancy</a> </p> <a href="https://publications.waset.org/abstracts/153138/a-case-report-on-the-multidisciplinary-approach-on-rectal-adenocarcinoma-in-pregnancy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/153138.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">174</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">144</span> Lipidomic Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Patricia%20O.%20Carvalho">Patricia O. Carvalho</a>, <a href="https://publications.waset.org/abstracts/search?q=Marcia%20C.%20F.%20Messias"> Marcia C. F. Messias</a>, <a href="https://publications.waset.org/abstracts/search?q=Salvador%20Sanchez%20Vinces"> Salvador Sanchez Vinces</a>, <a href="https://publications.waset.org/abstracts/search?q=Caroline%20F.%20A.%20Gatinoni"> Caroline F. A. Gatinoni</a>, <a href="https://publications.waset.org/abstracts/search?q=Vitor%20P.%20Iordanu"> Vitor P. Iordanu</a>, <a href="https://publications.waset.org/abstracts/search?q=Carlos%20A.%20R.%20Martinez"> Carlos A. R. Martinez</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Lipidomics methods are widely used in the identification and validation of disease-specific biomarkers and therapy response evaluation. The present study aimed to identify a panel of potential lipid biomarkers to evaluate response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma (RAC). Liquid chromatography–mass spectrometry (LC-MS)-based untargeted lipidomic was used to profile human serum samples from patients with clinical stage T2 or T3 resectable RAC, after and before chemoradiotherapy treatment. A total of 28 blood plasma samples were collected from 14 patients with RAC who recruited at the São Francisco University Hospital (HUSF/USF). The study was approved by the ethics committee (CAAE 14958819.8.0000.5514). Univariate and multivariate statistical analyses were applied to explore dysregulated metabolic pathways using untargeted lipidic profiling and data mining approaches. A total of 36 statistically significant altered lipids were identified and the subsequent partial least-squares discriminant analysis model was both cross validated (R2, Q2) and permutated. Lisophosphatidyl-choline (LPC) plasmalogens containing palmitoleic and oleic acids, with high variable importance in projection score, showed a tendency to be lower after completion of chemoradiotherapy. Chemoradiotherapy seems to change plasmanyl-phospholipids levels, indicating that these lipids play an important role in the RAC pathogenesis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=lipidomics" title="lipidomics">lipidomics</a>, <a href="https://publications.waset.org/abstracts/search?q=neoadjuvant%20chemoradiotherapy" title=" neoadjuvant chemoradiotherapy"> neoadjuvant chemoradiotherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=plasmalogens" title=" plasmalogens"> plasmalogens</a>, <a href="https://publications.waset.org/abstracts/search?q=rectal%20adenocarcinoma" title=" rectal adenocarcinoma"> rectal adenocarcinoma</a> </p> <a href="https://publications.waset.org/abstracts/135824/lipidomic-response-to-neoadjuvant-chemoradiotherapy-in-rectal-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/135824.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">131</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">143</span> Evaluation of the Radiolabelled 68GA-DOTATOC Complex in Adenocarcinoma Breast Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri">S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Naderi"> M. Naderi</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=B.%20Alirzapour"> B. Alirzapour</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20R.%20Jalilian"> A. R. Jalilian</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Ramazani"> A. Ramazani </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Nowadays, 68Ga-DOTATOC has been known as a potential agent for the detection of neuroendocrine tumours and it has indicated higher sensitivity compared with the 111In-Octeroetide. The aim of this study was to evaluate the effectiveness of this new agent in the diagnosis of adenocarcinoma breast cancer. 68Ga-DOTATOC was prepared with the radiochemical purity of higher than 98% and by the specific activity of 39.6 TBq/mmol. 37 MBq of the complex was injected intravenously into the BULB/c mice with adenocarcinoma breast cancer. PET/CT images were acquired after 30, 60 and 90 min post injection demonstrated significant accumulation in the tumour sites. Also, considerable activity was observed in the kidney and bladder as the main routs of excretion. Generally, the results showed that 68Ga-DOTATOC can be considered as a suitable complex for diagnosis of the adenocarcinoma breast cancer using PET procedure. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=adenocarcinoma%20breast%20cancer" title="adenocarcinoma breast cancer">adenocarcinoma breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=68Ga" title=" 68Ga"> 68Ga</a>, <a href="https://publications.waset.org/abstracts/search?q=octreotide" title=" octreotide"> octreotide</a>, <a href="https://publications.waset.org/abstracts/search?q=imaging" title=" imaging "> imaging </a> </p> <a href="https://publications.waset.org/abstracts/34303/evaluation-of-the-radiolabelled-68ga-dotatoc-complex-in-adenocarcinoma-breast-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/34303.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">341</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">142</span> The Colorectal Cancer in Patients of Eastern Algeria</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=S.%20Tebibel">S. Tebibel</a>, <a href="https://publications.waset.org/abstracts/search?q=C.%20Mechati"> C. Mechati</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Messaoudi"> S. Messaoudi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Algeria is currently experiencing the same rate of cancer progression as that registered these last years in the western countries. Colorectal cancer, constituting increasingly a major public health problem, is the most common form of cancer after breast and Neck-womb cancer at the woman and prostate cancer at the man. Our work is based on a retrospective study to determine the cases of colorectal cancer through eastern Algeria. Our goal is to carry out an epidemiological, histological and immune- histochemical study to investigate different techniques for the diagnosis of colorectal cancer and their interests and specific in detecting the disease. The study includes 110 patients (aged between 20 to 87 years) with colorectal cancer where the inclusions and exclusions criteria were established. In our study, colorectal cancer, expresses a male predominance, with a sex ratio of 1, 99 and the most affected age group is between 50 and 59 years. We noted that the colon cancer rate is higher than rectal cancer rate, whose frequencies are respectively 60,91 % and 39,09 %. In the series of colon cancer, the ADK lieberkunien is histological the most represented type, or 85,07 % of all cases. In contrast, the proportion of ADK mucinous (colloid mucous) is only 1,49% only. Well-differentiated ADKS, are very significant in our series, they represent 83,58 % of cases. Adenocarcinoma moderately and poorly differentiated, whose proportions are respectively 2,99 % and 0.05 %. For histological varieties of rectal ADK, we see in our workforce that ADK lieberkunien represent the most common histological form, or 76,74%, while the mucosal colloid is 13,95 %. Research of the mutation on the gene encoding K-ras, a major step in the targeted therapy of colorectal cancers, is underway in our study. Colorectal cancer is the subject of much promising research concern: the evaluation of new therapies (antiangiogenic monoclonal antibodies), the search for predictors of sensitivity to chemotherapy and new prognostic markers using techniques of molecular biology and proteomics. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=adenocarcinoma" title="adenocarcinoma">adenocarcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=age" title=" age"> age</a>, <a href="https://publications.waset.org/abstracts/search?q=colorectal%20cancer" title=" colorectal cancer"> colorectal cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=epidemiology" title=" epidemiology"> epidemiology</a>, <a href="https://publications.waset.org/abstracts/search?q=histological%20section" title=" histological section"> histological section</a>, <a href="https://publications.waset.org/abstracts/search?q=sex" title=" sex"> sex</a> </p> <a href="https://publications.waset.org/abstracts/42726/the-colorectal-cancer-in-patients-of-eastern-algeria" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/42726.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">344</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">141</span> Timing of Ileostomy Closure Following Rectal Cancer Surgery at an Australian Regional Hospital</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Tedman%20Cheuk-Yiu%20Chau">Tedman Cheuk-Yiu Chau</a>, <a href="https://publications.waset.org/abstracts/search?q=Xavier%20Harvey"> Xavier Harvey</a>, <a href="https://publications.waset.org/abstracts/search?q=Hung%20Nguyen"> Hung Nguyen</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Defunctioning ileostomies are frequently used as an adjunct to low anterior resection in the surgical treatment of rectal cancer. Despite reducing the rate of clinically relevant anastomotic leak, the burden of defunctioning ileostomy is significant, with up to two-thirds of patients reporting stoma-related morbidity. International data have demonstrated an increased risk of bowel dysfunction and lower quality of life in patients with delayed closure (greater than six months post-surgery). While timely reversal is safe and cost-effective, the time to the reversal in Australian and New Zealand public hospitals is not described in the published literature. Thus, it is important to assess the current timeliness of ileostomy closure in the Australian regional context and examine the reasons for the delay. A retrospective analysis of ileostomy closure in Launceston General Hospital (LGH) patients treated with low/ultra low anterior resection for rectal cancer between 2012 and 2019 was undertaken. 94 cases of rectal adenocarcinoma undergoing ultralow anterior resection were examined over the years between 2012-2019. Amongst these, 21 cases (22.3%) were not reversed due to disease progress, death prior to reversal, or surgical complication. Demographics, disease status, surgical technique, and hospital inpatient events of these cases were examined. An average waiting time of 213.2 days was noted. Reasons for the delay include non-specified/prolonged hospital waiting time (54%), delayed or complicated chemotherapy course (13%), surgical complication (11%), advanced age, and frailty(5%). Complication of a delayed ileostomy reversal includes post-operation ileus and the development of an incisional hernia. We conclude that a delayed reversal of ileostomy can contribute to a higher incidence of stoma-related co-morbidities and contribute to a longer hospital stay and therefore use of public hospital resources. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=anterior%20resection" title="anterior resection">anterior resection</a>, <a href="https://publications.waset.org/abstracts/search?q=colorectal%20surgery" title=" colorectal surgery"> colorectal surgery</a>, <a href="https://publications.waset.org/abstracts/search?q=ileostomy%20reversal" title=" ileostomy reversal"> ileostomy reversal</a>, <a href="https://publications.waset.org/abstracts/search?q=rectal%20cancer" title=" rectal cancer"> rectal cancer</a> </p> <a href="https://publications.waset.org/abstracts/157432/timing-of-ileostomy-closure-following-rectal-cancer-surgery-at-an-australian-regional-hospital" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/157432.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">95</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">140</span> Local and Systemic Complications after Resection of Rectal Cancer in the Department of General and Abdominal Surgery University Clinical Center Maribor between 2004 and 2014</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nuhi%20Arslani">Nuhi Arslani</a>, <a href="https://publications.waset.org/abstracts/search?q=Stojan%20Potrc"> Stojan Potrc</a>, <a href="https://publications.waset.org/abstracts/search?q=Timotej%20Mikuljan"> Timotej Mikuljan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: In Department of Abdominal and General Surgery of University Medical Centre Maribor, we treated 578 patients for rectal cancer between 2004 and 2014. During and after treatment we especially concentrated on monitoring local and systemic complications. Methods: For analysis, we used data gathered from preoperative diagnostic tests, reports gathered during operation, reports from the pathohistologic review, and reports on complications after surgery and follow up. Results: In the case of 573 (out of 578) patients (99.1%) we performed resection. R0 was achieved in 551 patients (96,1%). R1 was achieved in 8 patients (1,4%). R2 was achieved in 14 patients (2,4%). Local complications were reported in 78 (13.5%) patients and systemic complications were reported in 68 (11.7%). We would like to point out the low number of local and systemic complications. Conclusions: With advances in surgical techniques, with a multimodal-multidisciplinary approach and with the use of total mesorectal excision we experienced a significant improvement in reducing the number of local and systemic complications in patients with rectal cancer. However, there still remains the question for truly optimal care for each patient with rectal cancer and his quality of life after surgical treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=local%20complications" title="local complications">local complications</a>, <a href="https://publications.waset.org/abstracts/search?q=rectal%20cancer" title=" rectal cancer"> rectal cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=resection" title=" resection"> resection</a>, <a href="https://publications.waset.org/abstracts/search?q=systemic%20complications" title=" systemic complications"> systemic complications</a> </p> <a href="https://publications.waset.org/abstracts/86026/local-and-systemic-complications-after-resection-of-rectal-cancer-in-the-department-of-general-and-abdominal-surgery-university-clinical-center-maribor-between-2004-and-2014" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/86026.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">167</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">139</span> ALDH1A1 as a Cancer Stem Cell Marker: Value of Immunohistochemical Expression in Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia, and Prostatic Adenocarcinoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20M.%20Abdelmoneim">H. M. Abdelmoneim</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20A.%20Babtain"> N. A. Babtain</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20S.%20Barhamain"> A. S. Barhamain</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Z.%20Kufiah"> A. Z. Kufiah</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20S.%20Malibari"> A. S. Malibari</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20F.%20Munassar"> S. F. Munassar</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20S.%20Rawa"> R. S. Rawa</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Prostate cancer is one of the most common causes of morbidity and mortality in men in developed countries. Cancer Stem Cells (CSCs) could be responsible for the progression and relapse of cancer. Therefore, CSCs markers could provide a prognostic strategy for human malignancies. Aldehyde dehydrogenase 1A1 (ALDH1A1) activity has been shown to be associated with tumorigenesis and proposed to represent a functional marker for tumor initiating cells in various tumor types including prostate cancer. Material & Methods: We analyzed the immunohistochemical expression of ALDH1A1 in benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma and assessed their significant correlations in 50 TURP sections. They were microscopically interpreted and the results were correlated with histopathological types and tumor grade. Results: In different prostatic histopathological lesions we found that ALDH1A1 expression was low in BPH (13.3%) and PIN (6.7%) and then its expression increased with prostatic adenocarcinoma (40%), and this was statistically highly significant (P value = 0.02). However, in different grades of prostatic adenocarcinoma we found that the higher the Gleason grade the higher the expression for ALDH1A1 and this was statistically significant (P value = 0.02). We compared the expression of ALDH1A1 in PIN and prostatic adenocarcinoma. ALDH1A1 expression was decreased in PIN and highly expressed in prostatic adenocarcinoma and this was statistically significant (P value = 0.04). Conclusion: Increasing ALDH1A1 expression is correlated with aggressive behavior of the tumor. Immunohistochemical expression of ALDH1A1 might provide a potential approach to study tumorigenesis and progression of primary prostate carcinoma. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=ALDH1A1" title="ALDH1A1">ALDH1A1</a>, <a href="https://publications.waset.org/abstracts/search?q=BPH" title=" BPH"> BPH</a>, <a href="https://publications.waset.org/abstracts/search?q=PIN" title=" PIN"> PIN</a>, <a href="https://publications.waset.org/abstracts/search?q=prostatic%20adenocarcinoma" title=" prostatic adenocarcinoma"> prostatic adenocarcinoma</a> </p> <a href="https://publications.waset.org/abstracts/43391/aldh1a1-as-a-cancer-stem-cell-marker-value-of-immunohistochemical-expression-in-benign-prostatic-hyperplasia-prostatic-intraepithelial-neoplasia-and-prostatic-adenocarcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/43391.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">262</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">138</span> Cytotoxic Activity of Extracts from Hibiscus sabdariffa Leaves against Women’s Cancer Cell Lines</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Patsorn%20Worawattananutai">Patsorn Worawattananutai</a>, <a href="https://publications.waset.org/abstracts/search?q=Srisopa%20Ruangnoo"> Srisopa Ruangnoo</a>, <a href="https://publications.waset.org/abstracts/search?q=Arunporn%20Itharat"> Arunporn Itharat</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hibiscus sabdariffa (HS) leaves are vegetables which are extensively used as blood tonic and laxatives in Thai traditional medicine. They are popularly used as healthy sour soup for prevention of chronic diseases such as cancer. Therefore, the cytotoxic activity of different extracts of fresh and dried Hibiscus sabdariffa leaves were investigated via the sulforhodamine B (SRB) assay against three types of women’s cancer cell lines, namely the human cervical adenocarcinoma cell line (HeLa), the human ovarian adenocarcinoma cell line (SKOV-3), and the human breast adenocarcinoma cell line (MCF-7). Extraction methods were squeezing, boiling with water and maceration with 95% or 50% ethanol. The 95% ethanolic extracts of Hibiscus sabdariffa dry leaves (HSDE95) showed the highest cytotoxicity against all types of women’s cancer cell lines with the IC50 values in range 7.51±0.33 to 12.13±1.85 µg/ml. Its IC50 values against SKOV-3, HeLa and MCF-7 were 7.51±0.33, 9.44±1.41 and 12.13±1.85 µg/ml, respectively. In these results, this extract can be classified as “active” according to the NCI guideline which indicated that IC50 values of the active cytotoxic plant extracts have to be beneath 20 µg/ml. Thus, HSDE95 was concluded to be a potent cytotoxic drug for all women’s cancer cells. This extract should be further investigated to isolate active compounds against women’s cancer cells. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20adenocarcinoma" title="breast adenocarcinoma">breast adenocarcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=cervical%20adenocarcinoma" title=" cervical adenocarcinoma"> cervical adenocarcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=cytotoxic%20activity" title=" cytotoxic activity"> cytotoxic activity</a>, <a href="https://publications.waset.org/abstracts/search?q=Hibiscus%20sabdariffa" title=" Hibiscus sabdariffa"> Hibiscus sabdariffa</a>, <a href="https://publications.waset.org/abstracts/search?q=ovarian%20adenocarcinoma" title=" ovarian adenocarcinoma"> ovarian adenocarcinoma</a> </p> <a href="https://publications.waset.org/abstracts/25269/cytotoxic-activity-of-extracts-from-hibiscus-sabdariffa-leaves-against-womens-cancer-cell-lines" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/25269.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">600</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">137</span> Prevalence of Chlamydia Trachomatis Infection in Multiple Anatomical Sites among Patients at Stis Center, Thailand</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Siwimol%20Phoomniyom">Siwimol Phoomniyom</a>, <a href="https://publications.waset.org/abstracts/search?q=Pathom%20Karaipoom"> Pathom Karaipoom</a>, <a href="https://publications.waset.org/abstracts/search?q=Rossaphorn%20Kittyaowaman"> Rossaphorn Kittyaowaman</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: C. trachomatis is the most common bacterial sexually transmitted infections. Although infection with C. trachomatis can be treated with antibiotic, it is frequently asymptomatic, especially in extragenital sites. Hence, if screening tests are not performed, undetected and untreated is a crucial problem for C. trachomatis infection, especially in Thailand, which is less well studied. We sought to assess the prevalence of C. trachomatis infection in multiple anatomical sites among patients attending Bangrak STIs Center. Methods: We examined laboratory results of all patients at baseline visit from 3 January 2018 to 27 December 2019. These results were tested by a validated in-house real time PCR specify for the cryptic plasmid gene of C. trachomatis. The prevalence of C. trachomatis was analyzed by anatomical sites, sexes, and ages. Urogenital samples were obtained from urethral swab of men and cervical swab of women. The median ages of the patients were 32 years (range 13-89 years). Chi-square test by IBM SPSS statistic version 20 was used to assess difference in the distribution of variables between groups. Results: Among 3,789 patients, the prevalence for C. trachomatis infection was the highest in rectal (16.1%), followed by urogenital (11.2%) and pharyngeal (3.5%) sites. Rectal and urogenital infection in men was higher than in women, with the highest prevalence of 16.6% in rectal site. Both rectal and urogenital sites also showed statistically significant differences between sexes (P<0.001). Meanwhile, pharyngeal C. trachomatis infection rate was higher in women than men. Interestingly, the chlamydia prevalence was the highest in age 13-19 years of all three sites (18.5%, urogenital; 17.7%, rectal; 6.5%, pharyngeal), with statistically significant difference between age groups (P<0.001). Total of 45 C. trachomatis infections, 20.0%, 51.1%, and 6.7% were isolated from urogenital, rectal, and pharyngeal sites. In total, 75.6%, 26.7%, and 80.0% of chlamydia infections would have been missed, if only urogenital, rectal, or pharyngeal screening was performed. Conclusions: The highest source of C. trachomatis infection was the rectal site. While, the highest prevalence in men was at rectal site, that in women was at urogenital site. The highest chlamydia prevalence was found in adolescent age group, indicating that the pediatric population was a high-risk group. This finding also elucidated that a high proportion of C. trachomatis infection would be missed, if only single anatomical site screening was performed, especially in extragenital sites. Hence, extragenital screening is also required for the extensive C. trachomatis detection. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chlamydia%20trachomatis" title="chlamydia trachomatis">chlamydia trachomatis</a>, <a href="https://publications.waset.org/abstracts/search?q=anatomical%20sites" title=" anatomical sites"> anatomical sites</a>, <a href="https://publications.waset.org/abstracts/search?q=sexes" title=" sexes"> sexes</a>, <a href="https://publications.waset.org/abstracts/search?q=ages" title=" ages"> ages</a> </p> <a href="https://publications.waset.org/abstracts/168884/prevalence-of-chlamydia-trachomatis-infection-in-multiple-anatomical-sites-among-patients-at-stis-center-thailand" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/168884.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">70</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">136</span> Endoscopic Ultrasound Guided Fine Needle Aspiration/Brush in Cytopathology Diagnosis: A Fifteen-Month Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Santosh%20Tummidi">Santosh Tummidi</a>, <a href="https://publications.waset.org/abstracts/search?q=Pragati%20Sathe"> Pragati Sathe</a>, <a href="https://publications.waset.org/abstracts/search?q=Kanchan%20Kothari"> Kanchan Kothari</a>, <a href="https://publications.waset.org/abstracts/search?q=Prachi%20Gholap"> Prachi Gholap</a>, <a href="https://publications.waset.org/abstracts/search?q=Mona%20Agnihotri"> Mona Agnihotri</a>, <a href="https://publications.waset.org/abstracts/search?q=Gwendolyn%20Fernandes"> Gwendolyn Fernandes</a>, <a href="https://publications.waset.org/abstracts/search?q=Leena%20Naik"> Leena Naik</a>, <a href="https://publications.waset.org/abstracts/search?q=Rachana%20Chaturvedi"> Rachana Chaturvedi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: EUS-Guided Fine Needle Aspiration/Brush (EUS-FNA/Brush) has become increasingly popular for the diagnosis and staging of gastrointestinal and peri-gastrointestinal lesions. Objective: To evaluate the diagnostic accuracy and spectrum of lesions in gastrointestinal EUS-FNA. Material and Methods: A total of 124 EUS-FNA during the period from Aug 2015-Nov 2016 were studied. Results: Age ranged from 13-80 years with a slight female predominance. CBD was the most common site with 47 cases amongst which were 9 adenocarcinoma, and 7 cases were suspicious for malignancy. Pancreatic EUS-FNA showed 5 adenocarcinoma, 2 SPEN, 1 case each of neuroendocrine tumor, anaplastic carcinoma and NHL. Amongst oesophageal lesions, 3 cases were suspicious for malignancy, and 4 were inflammatory, 4 showed SCC, 1case each adenocarcinoma and leiomyoma. Stomach- 1 case each of adenocarcinoma, granulomatous inflammation, and GIST. Periportal lymph nodes were the commonest nodes, and there were 11 necrotising granulomatous inflammations, 3 metastatic adenocarcinoma, 2 cases of atypical cells and 1 case of NHL. 17 cases were unsatisfactory, 41 cases had histopathology follow up with 85% cases being concordant. Conclusion: EUS-FNA is reliable, sensitive and specific. It can be utilized for better management of intra-abdominal lesions. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=EUS-FNA" title="EUS-FNA">EUS-FNA</a>, <a href="https://publications.waset.org/abstracts/search?q=brush" title=" brush"> brush</a>, <a href="https://publications.waset.org/abstracts/search?q=cytology" title=" cytology"> cytology</a>, <a href="https://publications.waset.org/abstracts/search?q=histopathology" title=" histopathology"> histopathology</a> </p> <a href="https://publications.waset.org/abstracts/69355/endoscopic-ultrasound-guided-fine-needle-aspirationbrush-in-cytopathology-diagnosis-a-fifteen-month-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/69355.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">304</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">135</span> A Randomised, Single-Dose, Two-Period, Cross-Over Phase I Pharmacokinetic Study to Compare TDS®-Diazepam with Rectal Diazepam in Healthy Adult Subjects</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Faisal%20O.%20Al-Otaibi">Faisal O. Al-Otaibi</a>, <a href="https://publications.waset.org/abstracts/search?q=Arthur%20T.%20Tucker"> Arthur T. Tucker</a>, <a href="https://publications.waset.org/abstracts/search?q=Richard%20M.%20Langford"> Richard M. Langford</a>, <a href="https://publications.waset.org/abstracts/search?q=Stuart%20Ratcliffe"> Stuart Ratcliffe</a>, <a href="https://publications.waset.org/abstracts/search?q=Atholl%0D%0AJohnston"> Atholl Johnston</a>, <a href="https://publications.waset.org/abstracts/search?q=Terry%20D.%20Lee"> Terry D. Lee</a>, <a href="https://publications.waset.org/abstracts/search?q=Kenneth%20B.%20Kirby"> Kenneth B. Kirby</a>, <a href="https://publications.waset.org/abstracts/search?q=Chandan%20A.%20Alam"> Chandan A. Alam</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The Transdermal Delivery System (TDS®) is a proprietary liquid formulation that can be applied to intact skin via a metered pump spray to facilitate drug delivery to the circulation. The aim of this study was to assess the ability of the TDS preparation to deliver diazepam systemically, and to characterize the pharmacokinetic profile of the drug in healthy adult subjects. We conducted a randomized, single-dose, two-period, crossover phase I (pharmacokinetic) comparative study in twelve healthy volunteers. All volunteers received both 10 mg TDS-diazepam topically to the upper chest and 10 mg of the rectal diazepam preparation (Diastat®, 10 mg diazepam gel), with a minimum washout of 14 days between dosing episodes. Both formulations were well tolerated in all volunteers. Following topical application of TDS-diazepam, the mean AUC0-72h was 1241 ng/mL.h and the Cmax 34 ng/mL. The values for rectal Diastat were 4109 ng/mL.h and 300 ng/mL respectively. This proof of concept study demonstrates that the TDS preparation successfully delivered diazepam systemically to adults. As expected, the concentration of diazepam following the TDS application was lower and not bioequivalent to rectal gel. Future development of this unique system is required. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=transdermal%20delivery%20system" title="transdermal delivery system">transdermal delivery system</a>, <a href="https://publications.waset.org/abstracts/search?q=diazepam" title=" diazepam"> diazepam</a>, <a href="https://publications.waset.org/abstracts/search?q=seizure" title=" seizure"> seizure</a>, <a href="https://publications.waset.org/abstracts/search?q=bioequivalence" title=" bioequivalence"> bioequivalence</a>, <a href="https://publications.waset.org/abstracts/search?q=pharmacokinetic" title=" pharmacokinetic"> pharmacokinetic</a> </p> <a href="https://publications.waset.org/abstracts/12728/a-randomised-single-dose-two-period-cross-over-phase-i-pharmacokinetic-study-to-compare-tds-diazepam-with-rectal-diazepam-in-healthy-adult-subjects" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/12728.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">425</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">134</span> Pancreatic Adenocarcinoma Correctly Diagnosed by EUS but nor CT or MRI </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yousef%20Reda">Yousef Reda</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Pancreatic cancer has an overall dismal prognosis. CT, MRI and Endoscopic Ultrasound are most often used to establish the diagnosis. We present a case of a patient found on abdominal CT and MRI to have an 8 mm cystic lesion within the head of the pancreas which was thought to be a benign intraductal papillary mucinous neoplasm (IPMN). Further evaluation by EUS demonstrated a 1 cm predominantly solid mass that was proven to be an adenocarcinoma by EUS-guided FNA. The patient underwent a Whipple procedure. The final pathology confirmed a 1 cm pT1 N0 pancreatic ductal adenocarcinoma. Case: A 63-year-old male presented with left upper quadrant pain and an abdominal CT demonstrated an 8 mm lesion within the head of the pancreas that was thought to represent a side branch IPMN. An MRI also showed similar findings. Four months later due to ongoing symptoms an EUS was performed to re-evaluate the pancreatic lesion. EUS revealed a predominantly solid hypoechoic, homogeneous mass measuring 12 mm x 9 mm. EUS-guided FNA was performed and was positive for adenocarcinoma. The patient underwent a Whipple procedure that confirmed it to be a ductal adenocarcinoma, pT1N0. The solid mass was noted to be adjacent to a cystic dilation with no papillary architecture and scant epithelium. The differential diagnosis resided between cystic degeneration of a primary pancreatic adenocarcinoma versus malignant degeneration within a side-branch IPMN. Discussion: The reported sensitivity of CT for pancreatic cancer is approximately 90%. For pancreatic tumors, less than 3 cm the sensitivity of CT is reduced ranging from 67-77%. MRI does not significantly improve overall detection rates compared to CT. EUS, however is superior to CT in the detection of pancreatic cancer, in particular among lesions smaller than 3 cm. EUS also outperforms CT and MRI in distinguishing neoplastic from non-neoplastic cysts. In this case, both MRI and CT failed to detect a small pancreatic adenocarcinoma. The addition of EUS and FNA to abdominal imaging can increase overall accuracy for the diagnosis of neoplastic pancreatic lesions. It may be prudent that when small lesions although appearing as a benign IPMN should further be evaluated by EUS as this would lead to potentially identifying earlier stage pancreatic cancers and improve survival in a disease which has a dismal prognosis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=IPMN" title="IPMN">IPMN</a>, <a href="https://publications.waset.org/abstracts/search?q=MRI" title=" MRI"> MRI</a>, <a href="https://publications.waset.org/abstracts/search?q=EUS" title=" EUS"> EUS</a>, <a href="https://publications.waset.org/abstracts/search?q=CT" title=" CT"> CT</a> </p> <a href="https://publications.waset.org/abstracts/40219/pancreatic-adenocarcinoma-correctly-diagnosed-by-eus-but-nor-ct-or-mri" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/40219.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">263</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">133</span> Utility of CK7, CK20 and CDX-2 as a Potential Panel in Differentiating Primary Ovarian Surface Epithelial Tumors from Metastatic Adenocarcinoma to the Ovary</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ghada%20Esheba">Ghada Esheba</a>, <a href="https://publications.waset.org/abstracts/search?q=Ghadeer%20Aldoobi"> Ghadeer Aldoobi</a>, <a href="https://publications.waset.org/abstracts/search?q=Salwa%20Almalk"> Salwa Almalk</a>, <a href="https://publications.waset.org/abstracts/search?q=Abrar%20Alshareef"> Abrar Alshareef</a>, <a href="https://publications.waset.org/abstracts/search?q=Eman%20Al-khairi"> Eman Al-khairi</a>, <a href="https://publications.waset.org/abstracts/search?q=Eman%20Yaseen"> Eman Yaseen</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: In Saudi Arabia, ovarian cancer ranked seventh among female population and is the most common female genital tract malignancy after endometrial cancer. A slight increase in the incidence of ovarian cancer was observed from 2001–2008. Makkah, Riyadh, and the eastern region of Saudi Arabia had the highest incidence rate ratio for the number of ovarian cancer cases (1). Differentiating metastatic adenocarcinomas from primary ovarian carcinomas, especially those of endometrioid and mucinous type is clinically signiﬁcant and a challenge for clinicians and pathologists, yet the distinction has important therapeutic and prognostic implications. Aim: To clarify the most important histopathological criteria to differentiate between primary ovarian surface epithelial tumors especially mucinous and endometrioid subtypes, and metastatic adenocarcinoma and to evaluate the value of a panel of antibodies consisting of CK7, CK20, and CDX-2 in the distinction between primary ovarian surface epithelial tumors and metastatic adenocarcinoma. Material and methods: This study was carried out on 26 cases of primary ovarian surface epithelial neoplasms and 14 cases of metastatic ovarian adenocarcinoma. All cases were studied immunohistochemically using CK7, CK20, and CDX-2. Results: All cases of primary ovarian adenocarcinoma were positive for CK7. 25% and 58% of mucinous borderline mucinous tumor and mucinous carcinoma respectively were positive for CK20. Only 42% of mucinous carcinoma were positive for CDX-2. All cases of endometrioid carcinomas were negative for both CK20 and CDX-2. All cases of metastatic adenocarcinoma from the colon were negative for CK7 and positive for CK20 and CDX-2. Conclusions: CK7 is an important positive marker for primary ovarian tumors, while CK20 and CDX-2 are useful markers for colorectal carcinoma metastatic to the ovary. Caution should be taken as primary ovarian mucinous tumors may stain positive for CK20, CDX-2, or both, however, they usually exhibit a focal pattern of reactivity. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=adenoma" title="adenoma">adenoma</a>, <a href="https://publications.waset.org/abstracts/search?q=endometrioid" title=" endometrioid"> endometrioid</a>, <a href="https://publications.waset.org/abstracts/search?q=malignancy" title=" malignancy"> malignancy</a>, <a href="https://publications.waset.org/abstracts/search?q=ovarian" title=" ovarian"> ovarian</a> </p> <a href="https://publications.waset.org/abstracts/43930/utility-of-ck7-ck20-and-cdx-2-as-a-potential-panel-in-differentiating-primary-ovarian-surface-epithelial-tumors-from-metastatic-adenocarcinoma-to-the-ovary" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/43930.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">232</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">132</span> Role of Imaging in Predicting the Receptor Positivity Status in Lung Adenocarcinoma: A Chapter in Radiogenomics</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sonal%20Sethi">Sonal Sethi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mukesh%20Yadav"> Mukesh Yadav</a>, <a href="https://publications.waset.org/abstracts/search?q=Abhimanyu%20Gupta"> Abhimanyu Gupta</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The upcoming field of radiogenomics has the potential to upgrade the role of imaging in lung cancer management by noninvasive characterization of tumor histology and genetic microenvironment. Receptor positivity like epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) genotyping are critical in lung adenocarcinoma for treatment. As conventional identification of receptor positivity is an invasive procedure, we analyzed the features on non-invasive computed tomography (CT), which predicts the receptor positivity in lung adenocarcinoma. Retrospectively, we did a comprehensive study from 77 proven lung adenocarcinoma patients with CT images, EGFR and ALK receptor genotyping, and clinical information. Total 22/77 patients were receptor-positive (15 had only EGFR mutation, 6 had ALK mutation, and 1 had both EGFR and ALK mutation). Various morphological characteristics and metastatic distribution on CT were analyzed along with the clinical information. Univariate and multivariable logistic regression analyses were used. On multivariable logistic regression analysis, we found spiculated margin, lymphangitic spread, air bronchogram, pleural effusion, and distant metastasis had a significant predictive value for receptor mutation status. On univariate analysis, air bronchogram and pleural effusion had significant individual predictive value. Conclusions: Receptor positive lung cancer has characteristic imaging features compared with nonreceptor positive lung adenocarcinoma. Since CT is routinely used in lung cancer diagnosis, we can predict the receptor positivity by a noninvasive technique and would follow a more aggressive algorithm for evaluation of distant metastases as well as for the treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=lung%20cancer" title="lung cancer">lung cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=multidisciplinary%20cancer%20care" title=" multidisciplinary cancer care"> multidisciplinary cancer care</a>, <a href="https://publications.waset.org/abstracts/search?q=oncologic%20imaging" title=" oncologic imaging"> oncologic imaging</a>, <a href="https://publications.waset.org/abstracts/search?q=radiobiology" title=" radiobiology"> radiobiology</a> </p> <a href="https://publications.waset.org/abstracts/129528/role-of-imaging-in-predicting-the-receptor-positivity-status-in-lung-adenocarcinoma-a-chapter-in-radiogenomics" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/129528.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">136</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">131</span> Cytotoxicity of 13 South African Macrofungal Species and Mechanism/s of Action against Cancer Cell Lines</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Gerhardt%20Boukes">Gerhardt Boukes</a>, <a href="https://publications.waset.org/abstracts/search?q=Maryna%20Van%20De%20Venter"> Maryna Van De Venter</a>, <a href="https://publications.waset.org/abstracts/search?q=Sharlene%20Govender"> Sharlene Govender</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Macrofungi have been used for the past two thousand years in Asian countries, and more recently in Western countries, for their medicinal properties. Biological activities include antimicrobial, antioxidant, anti-inflammatory, antidiabetic, anticancer and immunomodulatory to name a few. Several biologically active compounds have been identified and isolated. Macrofungal research in Africa is poorly documented and to the best of our knowledge non-existent. South Africa has a rich macrofungal biodiversity, which includes endemic and exotic macrofungal species. Ethanolic extracts of 13 macrofungal species, including mushrooms, bracket fungi and puffballs, were prepared and screened for cytotoxicity against a panel of seven cell lines, including A549 (human lung adenocarcinoma), HeLa (human cervical adenocarcinoma), HT-29 (human colorectal adenocarcinoma), MCF7 (human breast adenocarcinoma), MIA PaCa-2 (human pancreatic ductal adenocarcinoma), PC-3 (human prostate adenocarcinoma) and Vero (African green monkey kidney epithelial) cells using MTT. Cell lines were chosen according to the most prevalent cancer types affecting males and females in South Africa and globally, and the mutations they contain. Preliminary results have shown that three of the macrofungal genera, i.e. Fomitopsis, Gymnopilus and Pycnoporus, have shown cytotoxic activity, ranging between IC50 ~20 and 200 µg/mL. The molecular mechanism of action contributing to cell death investigated and being investigated include apoptosis (i.e. DNA cell cycle arrest, caspase-3 activation and mitochondrial membrane potential), autophagy (i.e. acridine orange and LC3B staining) and ER stress (i.e. thioflavin T staining and caspase-12) in the presence of melphalan, chloroquine and thapsigargin/tuncamycin as positive controls, respectively. The genus, Pycnoporus, has shown the best cytotoxicity of the three macrofungal genera. Future work will focus on the identification and isolation of novel active compounds and elucidating the mechanism/s of action. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cancer" title="cancer">cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=cytotoxicity" title=" cytotoxicity"> cytotoxicity</a>, <a href="https://publications.waset.org/abstracts/search?q=macrofungi" title=" macrofungi"> macrofungi</a>, <a href="https://publications.waset.org/abstracts/search?q=mechanism%2Fs%20of%20action" title=" mechanism/s of action"> mechanism/s of action</a> </p> <a href="https://publications.waset.org/abstracts/53098/cytotoxicity-of-13-south-african-macrofungal-species-and-mechanisms-of-action-against-cancer-cell-lines" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/53098.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">246</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">130</span> Absorbed Dose Estimation of 177Lu-DOTATOC in Adenocarcinoma Breast Cancer Bearing Mice</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri">S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Mousavi-Daramoroudi"> M. Mousavi-Daramoroudi</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Abbasi-Davani"> F. Abbasi-Davani </a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this study, the absorbed dose of human organs after injection of <sup>177</sup>Lu-DOTATOC was studied based on the biodistribution of the complex in adenocarcinoma breast cancer bearing mice. For this purpose, the biodistribution of the radiolabelled complex was studied and compartmental modeling was applied to calculate the absorbed dose with high precision. As expected, <sup>177</sup>Lu-DOTATOC illustrated a notable specific uptake in tumor and pancreas, organs with high level of somatostatin receptor on their surface and the effectiveness of the radio-conjugate for targeting of the breast adenocarcinoma tumors was indicated. The elicited results of modeling were the exponential equations, and those are utilized for obtaining the cumulated activity data by taking their integral. The results also exemplified that non-target absorbed-doses such as the liver, spleen and pancreas were approximately 0.008, 0.004, and 0.039, respectively. While these values were so much lower than target (tumor) absorbed-dose, it seems due to this low toxicity, this complex is a good agent for therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=%C2%B9%E2%81%B7%E2%81%B7Lu" title="¹⁷⁷Lu">¹⁷⁷Lu</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title=" breast cancer"> breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=compartmental%20modeling" title=" compartmental modeling"> compartmental modeling</a>, <a href="https://publications.waset.org/abstracts/search?q=dosimetry" title=" dosimetry"> dosimetry</a> </p> <a href="https://publications.waset.org/abstracts/97772/absorbed-dose-estimation-of-177lu-dotatoc-in-adenocarcinoma-breast-cancer-bearing-mice" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/97772.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">151</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">129</span> Biodistribution Studies of 177Lu-DOTATOC in Mouse Tumor Model: Possible Utilization in Adenocarcinoma Breast Cancer Treatment</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20Mousavi-Daramoroudi">M. Mousavi-Daramoroudi</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Yousefnia"> H. Yousefnia</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Abbasi-Davani"> F. Abbasi-Davani</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Zolghadri"> S. Zolghadri</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Kakaei"> S. Kakaei</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Despite the appropriate characteristics of <sup>177</sup>Lu and DOTATOC, to our best knowledge, the therapeutic benefit of <sup>177</sup>Lu-DOTATOC complex in breast cancer has not been reported until now. In this study, biodistribution of <sup>177</sup>Lu-DOTA-TOC in mouse tumor model for evaluation of possible utilization of this complex in breast cancer treatment was investigated.<sup>177</sup>Lu was prepared with the specific activity of 2.6-3 GBq.mg<sup>-1</sup> and radionuclidic purity higher than 99%. The radiolabeled complex was prepared in the optimized conditions with the radiochemical purity higher than 99%. The final solution was injected to the BALB/c mice with adenocarcinoma breast cancer. The biodistribution results showed major accumulation in the kidneys as the major excretion route and the somatostatin receptor-positive tissues such as pancreas compared with the other tissues. Also, significant uptake was observed in tumor even in longer time after injection. According to the results obtained in this research study, somatostatin receptors expressed in breast cancers can be targeted with DOTATOC analogues especially with <sup>177</sup>Lu-DOTATOC as an ideal therapeutic agent. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=%C2%B9%E2%81%B7%E2%81%B7Lu" title="¹⁷⁷Lu">¹⁷⁷Lu</a>, <a href="https://publications.waset.org/abstracts/search?q=adenocarcinoma%20breast%20cancer" title=" adenocarcinoma breast cancer"> adenocarcinoma breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=DOTATOC" title=" DOTATOC"> DOTATOC</a>, <a href="https://publications.waset.org/abstracts/search?q=BALB%2Fc%20mice" title=" BALB/c mice"> BALB/c mice</a> </p> <a href="https://publications.waset.org/abstracts/80226/biodistribution-studies-of-177lu-dotatoc-in-mouse-tumor-model-possible-utilization-in-adenocarcinoma-breast-cancer-treatment" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/80226.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">227</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">128</span> Synthesis and Biological Activity Evaluation of U Complexes</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Kazem%20Mohammadi">Mohammad Kazem Mohammadi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The use of anticancer agents forms an important part of the treatment of cancer of various types. Uranyl Complexes with DPHMP ligand have been used for the prevention and treatment of cancers. U(IV) metal complexes prepared by reaction of uranyl salt UO2 (NO3)2.6H2O with DPHMP in dry acetonitrile. Characterization of the ligand and its complexes was made by microanalyses, FT-IR, 1H NMR, 13C NMR and UV–Visible spectroscopy. These new complex showed excellent antitumor activity against two kinds of cancer cells that that are HT29:Haman colon adenocarcinoma cell line and T47D:human breast adenocarcinoma cell line. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=uranyl%20complexes" title="uranyl complexes">uranyl complexes</a>, <a href="https://publications.waset.org/abstracts/search?q=DPHMP%20ligand" title=" DPHMP ligand"> DPHMP ligand</a>, <a href="https://publications.waset.org/abstracts/search?q=antitumor%20activity" title=" antitumor activity"> antitumor activity</a>, <a href="https://publications.waset.org/abstracts/search?q=HT29" title=" HT29"> HT29</a>, <a href="https://publications.waset.org/abstracts/search?q=T47D" title=" T47D"> T47D</a> </p> <a href="https://publications.waset.org/abstracts/23976/synthesis-and-biological-activity-evaluation-of-u-complexes" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/23976.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">469</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">127</span> A Case of Apocrine Sweat Gland Adenocarcinoma in a Tabby Cat</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Funda%20Terzi">Funda Terzi</a>, <a href="https://publications.waset.org/abstracts/search?q=Elif%20Dogan"> Elif Dogan</a>, <a href="https://publications.waset.org/abstracts/search?q=Ayse%20B.%20Kapcak"> Ayse B. Kapcak</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this report, clinical, radiological, macroscopic, and histopathological findings of apocrine sweat gland adenocarcinoma are presented in a 13-year-old male tabby cat. In clinical examination, soft tissue masses were detected in the caudal abdomen and left tuber coxae. On radiological examination, subcutaneous masses with soft tissue contrast appearance were detected, and the masses were surgically removed under general anesthesia. The sizes of the masses were approximately 2x2x3 cm in the caudal abdomen and approximately 1x1x2 cm in the tuber coxae region. The cross-section of the mass was whitish-yellow in color. After the masses were fixed in 10% formaldehyde solution, a routine histopathology procedure was applied. In histopathological examination, apocrine sweat glands in a cystic structure and extensions from the center of the cyst to the lumen were determined, and anisonucleosis, anisocytosis, and anaplastic cells with giant nuclei were observed in the epithelial cells of the gland facing the lumen. A diagnosis of papillary-cystic type apocrine sweat gland adenocarcinoma was made with these findings. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=apocrine%20sweat%20gland" title="apocrine sweat gland">apocrine sweat gland</a>, <a href="https://publications.waset.org/abstracts/search?q=carcinoma" title=" carcinoma"> carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=cat" title=" cat"> cat</a>, <a href="https://publications.waset.org/abstracts/search?q=histopathology" title=" histopathology"> histopathology</a> </p> <a href="https://publications.waset.org/abstracts/133466/a-case-of-apocrine-sweat-gland-adenocarcinoma-in-a-tabby-cat" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/133466.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">176</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">126</span> A Deep-Learning Based Prediction of Pancreatic Adenocarcinoma with Electronic Health Records from the State of Maine</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Xiaodong%20Li">Xiaodong Li</a>, <a href="https://publications.waset.org/abstracts/search?q=Peng%20Gao"> Peng Gao</a>, <a href="https://publications.waset.org/abstracts/search?q=Chao-Jung%20Huang"> Chao-Jung Huang</a>, <a href="https://publications.waset.org/abstracts/search?q=Shiying%20Hao"> Shiying Hao</a>, <a href="https://publications.waset.org/abstracts/search?q=Xuefeng%20B.%20Ling"> Xuefeng B. Ling</a>, <a href="https://publications.waset.org/abstracts/search?q=Yongxia%20Han">Yongxia Han</a>, <a href="https://publications.waset.org/abstracts/search?q=Yaqi%20Zhang"> Yaqi Zhang</a>, <a href="https://publications.waset.org/abstracts/search?q=Le%20Zheng"> Le Zheng</a>, <a href="https://publications.waset.org/abstracts/search?q=Chengyin%20Ye"> Chengyin Ye</a>, <a href="https://publications.waset.org/abstracts/search?q=Modi%20Liu"> Modi Liu</a>, <a href="https://publications.waset.org/abstracts/search?q=Minjie%20Xia"> Minjie Xia</a>, <a href="https://publications.waset.org/abstracts/search?q=Changlin%20Fu"> Changlin Fu</a>, <a href="https://publications.waset.org/abstracts/search?q=Bo%20Jin"> Bo Jin</a>, <a href="https://publications.waset.org/abstracts/search?q=Karl%20G.%20Sylvester"> Karl G. Sylvester</a>, <a href="https://publications.waset.org/abstracts/search?q=Eric%20Widen"> Eric Widen</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Predicting the risk of Pancreatic Adenocarcinoma (PA) in advance can benefit the quality of care and potentially reduce population mortality and morbidity. The aim of this study was to develop and prospectively validate a risk prediction model to identify patients at risk of new incident PA as early as 3 months before the onset of PA in a statewide, general population in Maine. The PA prediction model was developed using Deep Neural Networks, a deep learning algorithm, with a 2-year electronic-health-record (EHR) cohort. Prospective results showed that our model identified 54.35% of all inpatient episodes of PA, and 91.20% of all PA that required subsequent chemoradiotherapy, with a lead-time of up to 3 months and a true alert of 67.62%. The risk assessment tool has attained an improved discriminative ability. It can be immediately deployed to the health system to provide automatic early warnings to adults at risk of PA. It has potential to identify personalized risk factors to facilitate customized PA interventions. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cancer%20prediction" title="cancer prediction">cancer prediction</a>, <a href="https://publications.waset.org/abstracts/search?q=deep%20learning" title=" deep learning"> deep learning</a>, <a href="https://publications.waset.org/abstracts/search?q=electronic%20health%20records" title=" electronic health records"> electronic health records</a>, <a href="https://publications.waset.org/abstracts/search?q=pancreatic%20adenocarcinoma" title=" pancreatic adenocarcinoma"> pancreatic adenocarcinoma</a> </p> <a href="https://publications.waset.org/abstracts/129535/a-deep-learning-based-prediction-of-pancreatic-adenocarcinoma-with-electronic-health-records-from-the-state-of-maine" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/129535.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">155</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">125</span> Isolation of Cytotoxic Compound from Tectona grandis Stem to Be Used as Thai Medicinal Preparation for Cancer Treatment</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Onmanee%20Prajuabjinda">Onmanee Prajuabjinda</a>, <a href="https://publications.waset.org/abstracts/search?q=Pakakrong%20Thondeeying"> Pakakrong Thondeeying</a>, <a href="https://publications.waset.org/abstracts/search?q=Jipisute%20Chunthorng-Orn"> Jipisute Chunthorng-Orn</a>, <a href="https://publications.waset.org/abstracts/search?q=Bhanuz%20Dechayont"> Bhanuz Dechayont</a>, <a href="https://publications.waset.org/abstracts/search?q=Arunporn%20Itharat"> Arunporn Itharat </a> </p> <p class="card-text"><strong>Abstract:</strong></p> A Thai medicinal preparation has been used for cancer treatment more than ten years ago in Khampramong Temple. Tectona grandis stem is one ingredient of this Thai medicinal remedy. The ethanolic extract of Tectona grandis stem showed the highest cytotoxic activities against human breast adenocarcinoma (MCF-7), but was less cytotoxic against large cell lung carcinoma (COR-L23) (IC50 = 3.92 and 7.78 µg/ml, respectively). It was isolated by bioassay-guided isolation method. Tectoquinone, a anthraquinone compound was isolated from this plant. This compound showed high specific cytotoxicity against human breast adenocarcinoma (MCF-7), but was less cytotoxic against large cell lung carcinoma (COR-L23)(IC50 =16.15 and 47.56 µg/ml or 72.67 and 214.00 µM, respectively). However, it showed less cytotoxic activity than the crude extract. In conclusion, tectoquinone as a main compound, is not the best cytotoxic compound from Tectona grandis, so there are more active cytotoxic compounds in this extract which should be isolated in the future. Moreover, tectoquinone displayed specific cytotoxicity against only human breast adenocarcinoma (MCF-7) which is a good criterion for cancer treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Tectona%20grandis" title="Tectona grandis">Tectona grandis</a>, <a href="https://publications.waset.org/abstracts/search?q=SRB%20assay" title=" SRB assay"> SRB assay</a>, <a href="https://publications.waset.org/abstracts/search?q=cytotoxicity" title=" cytotoxicity"> cytotoxicity</a>, <a href="https://publications.waset.org/abstracts/search?q=tectoquinone" title=" tectoquinone"> tectoquinone</a> </p> <a href="https://publications.waset.org/abstracts/25415/isolation-of-cytotoxic-compound-from-tectona-grandis-stem-to-be-used-as-thai-medicinal-preparation-for-cancer-treatment" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/25415.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">432</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">124</span> Esophageal Premalignant and Malignant Epithelial Lesions: Pathological Characteristics and Value of Cyclooxygenase-2 Expression. </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hanan%20Mohamed%20Abd%20Elmoneim">Hanan Mohamed Abd Elmoneim</a>, <a href="https://publications.waset.org/abstracts/search?q=Rawan%20Saleh%20AlJawi"> Rawan Saleh AlJawi</a>, <a href="https://publications.waset.org/abstracts/search?q=Razan%20Saleh%20AlJawi"> Razan Saleh AlJawi</a>, <a href="https://publications.waset.org/abstracts/search?q=Aseel%20Abdullah%20AlMasoudi"> Aseel Abdullah AlMasoudi </a>, <a href="https://publications.waset.org/abstracts/search?q=Zyad%20Adnan%20Turkistani"> Zyad Adnan Turkistani</a>, <a href="https://publications.waset.org/abstracts/search?q=Anas%20Abdulkarim%20Alkhoutani"> Anas Abdulkarim Alkhoutani </a>, <a href="https://publications.waset.org/abstracts/search?q=Ohood%20Musaed%20AlJuhani"> Ohood Musaed AlJuhani </a>, <a href="https://publications.waset.org/abstracts/search?q=Hanan%20Attiyah%20AlZahrani"> Hanan Attiyah AlZahrani</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background Esophageal cancer is the eighth most common cancer worldwide. More than 90% of esophageal cancers are either squamous cell carcinoma or adenocarcinoma. Squamous dysplasia is a precancerous lesion for squamous cell carcinoma and Barrett's esophagus is the precancerous lesion for adenocarcinoma. Gastro-esophageal reflux disease (GERD) is the initiation factor for Barrett's esophagus. Cyclooxygenase-2 (COX-2) is a key enzyme in arachidonic metabolism. It appears to play an important role in gastrointestinal carcinogenesis. COX-2 activity may be a potential target for the prevention of cancer progression by selective COX-2 inhibitors, which decrease proliferation and increase apoptosis. Objectives To assess COX-2 expression in premalignant and malignant esophageal epitheliums changes and detect its roles in progression of these lesions. Materials and Methods We analyzed the expression of COX-2 immunohistochemically in 40 esophageal biopsies utilizing the streptavidin-biotin-peroxidase complex method on archival formalin fixed-paraffin embedded blocks. Histopathologically, 17 (42.5%) of cases were non-malignant cases which included GERD, Barrett's esophagus and squamous dysplasia. The malignant cases were 23 (57.5%) squamous cell carcinoma, adenocarcinoma and undifferentiated carcinoma. Results In non-malignant cases 7 (41.2%) out of 17 cases had high COX-2 expression. In squamous cell carcinoma 10 (83.3%) out of 12 cases had high COX-2 expression. The expression of COX-2 was high in all 9 (100%) cases of adenocarcinoma. COX-2 expression is significantly increased (P=0.005 and P=0.0001) in squamous cell carcinoma and adenocarcinoma respectively. There was a significant difference in COX-2 immunoreactivity between malignant and non-malignant lesions (P=0.0003). Conclusion COX-2 is responsible for the progression of esophageal diseases from benign to malignant. We recommend that COX-2 immunohistochemistry should be done routinely for premalignant and malignant esophageal lesions as selective COX-2 inhibitors will be helpful in the treatment. Further studies on molecular and genetic basis of COX-2 expression are needed to unmask its role and relation to progression of esophageal lesions. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Cox-2" title="Cox-2">Cox-2</a>, <a href="https://publications.waset.org/abstracts/search?q=Esophageal%20adinocarcinoma" title=" Esophageal adinocarcinoma"> Esophageal adinocarcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=Esophageal%20squamous%20cell%20carcinoma" title=" Esophageal squamous cell carcinoma"> Esophageal squamous cell carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=Immunohistochemistry." title=" Immunohistochemistry. "> Immunohistochemistry. </a> </p> <a href="https://publications.waset.org/abstracts/43810/esophageal-premalignant-and-malignant-epithelial-lesions-pathological-characteristics-and-value-of-cyclooxygenase-2-expression" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/43810.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">350</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">123</span> Role of Total Neoadjuvant Therapy in Sphincter Preservation in Locally Advanced Rectal Cancer: A Case Series</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Arpit%20Gite">Arpit Gite</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose: We have evaluated the role of Total Neoadjuvant Therapy in patients with Locally Advanced Rectal cancer by giving Chemoradiotherapy followed by consolidation chemotherapy (CRT-CNCT) and, after that, the strategy of wait and watch. Methods: In this prospective case series, we evaluated the results of three locally advanced Rectal cancers, two cases Stage II (cT3N0) and one case Stage III ( cT4aN2). All three patients' growth was 4-6 cm from the anal verge. We have treated with Chemoradiotherapy to dose of 45Gy/25 Fractions to elective nodal regions (Inguinal node in anal canal Involvement)and Primary and mesorectum (Phase I) followed by 14.4Gy/8 Fractions to Primary and Mesorectum(Phase II) to a total dose of 59.4Gy/33 Fractions with concurrent chemotherapy Tab Capecitabine 825mg/m2 PO BD with Radiation therapy. After 6 weeks of completion of Chemoradiotherapy, advised six cycles of consolidative chemotherapy, CAPEOX regimen, Oxaliplatin 130mg/m2 on day 1 and Capecitabine 1000mg/m2 PO BD on days 1-14 repeated on a 21-day cycle for a total of six cycles. The primary endpoint is Disease-free survival (DFS); the secondary endpoint is adverse events related to chemoradiotherapy. Radiation toxicity is assessed by RTOG criteria, and chemotherapy toxicity is assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Results: After 6 weeks of completion of Chemoradiotherapy, we did PET-CT of all three patients; all three patients had a clinically complete response and we advised 6 cycles of consolidative chemotherapy. After completion of consolidative chemotherapy, again PET-CT and sigmoidoscopy, all three patients had complete response on PET-CT and no lesions on sigmoidoscopy and kept all three patients on wait and watch.2 patients had Grade 2 skin toxicities,1 patient had Grade 1 skin toxicity, .2 patients had Grade 2 lower GI toxicities, and 1 patient had Grade lower GI toxicity, both according to RTOG criteria. 3 patients had Grade 2 diarrhea due to capecitabine, and 1 patient had Grade 1 thrombocytopenia due to oxaliplatin assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Conclusion: Sphincter Preservation is possible with this regimen in those who don’t want to opt for surgery or in case of low-lying rectal cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=locally%20advanced%20rectal%20cancer" title="locally advanced rectal cancer">locally advanced rectal cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=sphincter%20preservation" title=" sphincter preservation"> sphincter preservation</a>, <a href="https://publications.waset.org/abstracts/search?q=chemoradiotherapy" title=" chemoradiotherapy"> chemoradiotherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=consolidative%20chemotherapy" title=" consolidative chemotherapy"> consolidative chemotherapy</a> </p> <a href="https://publications.waset.org/abstracts/187035/role-of-total-neoadjuvant-therapy-in-sphincter-preservation-in-locally-advanced-rectal-cancer-a-case-series" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/187035.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">40</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">122</span> Significant Factor of Magnetic Resonance for Survival Outcome in Rectal Cancer Patients Following Neoadjuvant Combined Chemotherapy and Radiation Therapy: Stratification of Lateral Pelvic Lymph Node</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Min%20Ju%20Kim">Min Ju Kim</a>, <a href="https://publications.waset.org/abstracts/search?q=Beom%20Jin%20Park"> Beom Jin Park</a>, <a href="https://publications.waset.org/abstracts/search?q=Deuk%20Jae%20Sung"> Deuk Jae Sung</a>, <a href="https://publications.waset.org/abstracts/search?q=Na%20Yeon%20Han"> Na Yeon Han</a>, <a href="https://publications.waset.org/abstracts/search?q=Kichoon%20Sim"> Kichoon Sim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose: The purpose of this study is to determine the significant magnetic resonance (MR) imaging factors of lateral pelvic lymph node (LPLN) on the assessment of survival outcomes of neoadjuvant combined chemotherapy and radiation therapy (CRT) in patients with mid/low rectal cancer. Materials and Methods: The institutional review board approved this retrospective study of 63 patients with mid/low rectal cancer who underwent MR before and after CRT and patient consent was not required. Surgery performed within 4 weeks after CRT. The location of LPLNs was divided into following four groups; 1) common iliac, 2) external iliac, 3) obturator, and 4) internal iliac lymph nodes. The short and long axis diameters, numbers, shape (ovoid vs round), signal intensity (homogenous vs heterogenous), margin (smooth vs irregular), and diffusion-weighted restriction of LPLN were analyzed on pre- and post-CRT images. For treatment response using size, lymph node groups were defined as group 1) short axis diameter ≤ 5mm on both MR, group 2) > 5mm change into ≤ 5mm after CRT, and group 3) persistent size > 5mm before and after CRT. Clinical findings were also evaluated. The disease-free survival and overall survival rate were evaluated and the risk factors for survival outcomes were analyzed using cox regression analysis. Results: Patients in the group 3 (persistent size >5mm) showed significantly lower survival rates than the group 1 and 2 (Disease-free survival rates of 36.1% and 78.8, 88.8%, p < 0.001). The size response (group 1-3), multiplicity of LPLN, the level of carcinoembryonic antigen (CEA), patient’s age, T and N stage, vessel invasion, perineural invasion were significant factors affecting disease-free survival rate or overall survival rate using univariate analysis (p < 0.05). The persistent size (group 3) and multiplicity of LPLN were independent risk factors among MR imaging features influencing disease-free survival rate (HR = 10.087, p < 0.05; HR = 4.808, p < 0.05). Perineural invasion and T stage were shown as independent histologic risk factors (HR = 16.594, p < 0.05; HR = 15.891, p < 0.05). Conclusion: The persistent size greater than 5mm and multiplicity of LPLN on both pre- and post-MR after CRT were significant MR factors affecting survival outcomes in the patients with mid/low rectal cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=rectal%20cancer" title="rectal cancer">rectal cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=MRI" title=" MRI"> MRI</a>, <a href="https://publications.waset.org/abstracts/search?q=lymph%20node" title=" lymph node"> lymph node</a>, <a href="https://publications.waset.org/abstracts/search?q=combined%20chemoradiotherapy" title=" combined chemoradiotherapy"> combined chemoradiotherapy</a> </p> <a href="https://publications.waset.org/abstracts/99639/significant-factor-of-magnetic-resonance-for-survival-outcome-in-rectal-cancer-patients-following-neoadjuvant-combined-chemotherapy-and-radiation-therapy-stratification-of-lateral-pelvic-lymph-node" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/99639.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">150</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">121</span> Time-Interval between Rectal Cancer Surgery and Reintervention for Anastomotic Leakage and the Effects of a Defunctioning Stoma: A Dutch Population-Based Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Anne-Loes%20K.%20Warps">Anne-Loes K. Warps</a>, <a href="https://publications.waset.org/abstracts/search?q=Rob%20A.%20E.%20M.%20Tollenaar"> Rob A. E. M. Tollenaar</a>, <a href="https://publications.waset.org/abstracts/search?q=Pieter%20J.%20Tanis"> Pieter J. Tanis</a>, <a href="https://publications.waset.org/abstracts/search?q=Jan%20Willem%20T.%20Dekker"> Jan Willem T. Dekker</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Anastomotic leakage after colorectal cancer surgery remains a severe complication. Early diagnosis and treatment are essential to prevent further adverse outcomes. In the literature, it has been suggested that earlier reintervention is associated with better survival, but anastomotic leakage can occur with a highly variable time interval to index surgery. This study aims to evaluate the time-interval between rectal cancer resection with primary anastomosis creation and reoperation, in relation to short-term outcomes, stratified for the use of a defunctioning stoma. Methods: Data of all primary rectal cancer patients that underwent elective resection with primary anastomosis during 2013-2019 were extracted from the Dutch ColoRectal Audit. Analyses were stratified for defunctioning stoma. Anastomotic leakage was defined as a defect of the intestinal wall or abscess at the site of the colorectal anastomosis for which a reintervention was required within 30 days. Primary outcomes were new stoma construction, mortality, ICU admission, prolonged hospital stay and readmission. The association between time to reoperation and outcome was evaluated in three ways: Per 2 days, before versus on or after postoperative day 5 and during primary versus readmission. Results: In total 10,772 rectal cancer patients underwent resection with primary anastomosis. A defunctioning stoma was made in 46.6% of patients. These patients had a lower anastomotic leakage rate (8.2% vs. 11.6%, p < 0.001) and less often underwent a reoperation (45.3% vs. 88.7%, p < 0.001). Early reoperations (< 5 days) had the highest complication and mortality rate. Thereafter the distribution of adverse outcomes was more spread over the 30-day postoperative period for patients with a defunctioning stoma. Median time-interval from primary resection to reoperation for defunctioning stoma patients was 7 days (IQR 4-14) versus 5 days (IQR 3-13 days) for no-defunctioning stoma patients. The mortality rate after primary resection and reoperation were comparable (resp. for defunctioning vs. no-defunctioning stoma 1.0% vs. 0.7%, P=0.106 and 5.0% vs. 2.3%, P=0.107). Conclusion: This study demonstrated that early reinterventions after anastomotic leakage are associated with worse outcomes (i.e. mortality). Maybe the combination of a physiological dip in the cellular immune response and release of cytokines following surgery, as well as a release of endotoxins caused by the bacteremia originating from the leakage, leads to a more profound sepsis. Another explanation might be that early leaks are not contained to the pelvis, leading to a more profound sepsis requiring early reoperations. Leakage with or without defunctioning stoma resulted in a different type of reinterventions and time-interval between surgery and reoperation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=rectal%20cancer%20surgery" title="rectal cancer surgery">rectal cancer surgery</a>, <a href="https://publications.waset.org/abstracts/search?q=defunctioning%20stoma" title=" defunctioning stoma"> defunctioning stoma</a>, <a href="https://publications.waset.org/abstracts/search?q=anastomotic%20leakage" title=" anastomotic leakage"> anastomotic leakage</a>, <a href="https://publications.waset.org/abstracts/search?q=time-interval%20to%20reoperation" title=" time-interval to reoperation"> time-interval to reoperation</a> </p> <a href="https://publications.waset.org/abstracts/134233/time-interval-between-rectal-cancer-surgery-and-reintervention-for-anastomotic-leakage-and-the-effects-of-a-defunctioning-stoma-a-dutch-population-based-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/134233.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">138</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">120</span> DOG1 Expression Is in Common Human Tumors: A Tissue Microarray Study on More than 15,000 Tissue Samples</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kristina%20Jansen">Kristina Jansen</a>, <a href="https://publications.waset.org/abstracts/search?q=Maximilian%20Lennartz"> Maximilian Lennartz</a>, <a href="https://publications.waset.org/abstracts/search?q=Patrick%20Lebok"> Patrick Lebok</a>, <a href="https://publications.waset.org/abstracts/search?q=Guido%20Sauter"> Guido Sauter</a>, <a href="https://publications.waset.org/abstracts/search?q=Ronald%20Simon"> Ronald Simon</a>, <a href="https://publications.waset.org/abstracts/search?q=David%20Dum"> David Dum</a>, <a href="https://publications.waset.org/abstracts/search?q=Stefan%20Steurer"> Stefan Steurer</a> </p> <p class="card-text"><strong>Abstract:</strong></p> DOG1 (Discovered on GIST1) is a voltage-gated calcium-activated chloride and bicarbonate channel that is highly expressed in interstitial cells of Cajal and in gastrointestinal stromal tumors (GIST) derived from Cajal cells. To systematically determine in what tumor entities and normal tissue types DOG1 may be further expressed, a tissue microarray (TMA) containing 15,965 samples from 121 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. DOG1 immunostaining was found in 67 tumor types, including GIST (95.7%), esophageal squamous cell carcinoma (31.9%), pancreatic ductal adenocarcinoma (33.6%), adenocarcinoma of the Papilla Vateri (20%), squamous cell carcinoma of the vulva (15.8%) and the oral cavity (15.3%), mucinous ovarian cancer (15.3%), esophageal adenocarcinoma (12.5%), endometrioid endometrial cancer (12.1%), neuroendocrine carcinoma of the colon (11.1%) and diffuse gastric adenocarcinoma (11%). Low level-DOG1 immunostaining was seen in 17 additional tumor entities. DOG1 expression was unrelated to histopathological parameters of tumor aggressiveness and/or patient prognosis in cancers of the breast (n=1,002), urinary bladder (975), ovary (469), endometrium (173), stomach (233), and thyroid gland (512). High DOG1 expression was linked to estrogen receptor expression in breast cancer (p<0.0001) and the absence of HPV infection in squamous cell carcinomas (p=0.0008). In conclusion, our data identify several tumor entities that can show DOG1 expression levels at similar levels as in GIST. Although DOG1 is tightly linked to a diagnosis of GIST in spindle cell tumors, the differential diagnosis is much broader in DOG1 positive epithelioid neoplasms. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biomarker" title="biomarker">biomarker</a>, <a href="https://publications.waset.org/abstracts/search?q=DOG1" title=" DOG1"> DOG1</a>, <a href="https://publications.waset.org/abstracts/search?q=immunohistochemistry" title=" immunohistochemistry"> immunohistochemistry</a>, <a href="https://publications.waset.org/abstracts/search?q=tissue%20microarray" title=" tissue microarray"> tissue microarray</a> </p> <a href="https://publications.waset.org/abstracts/138403/dog1-expression-is-in-common-human-tumors-a-tissue-microarray-study-on-more-than-15000-tissue-samples" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/138403.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">216</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">119</span> Synthesis and Anti-Cancer Evaluation of Uranyle Complexes</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Abdol-Hassan%20Doulah">Abdol-Hassan Doulah</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this research, some of the inorganic complexes of uranyl with N- donor ligands were synthesized. Complexes were characteriezed by FT-IR and UV spectra, ¹HNMR, ¹³CNMR and some physical properties. The uranyl unit (UO2) is composed of a center of uranium atom with the charge (+6) and two oxygen atom by forming two U=O double bonds. The structure is linear (O=U=O, 180) and usually stable. So other ligands often coordinate to the U atom in the plane perpendicularly to the O=U=O axis. The antitumor activity of some of ligand and their complexes against a panel of human tumor cell lines (HT29: Haman colon adenocarcinoma cell line T47D: human breast adenocarcinoma cell line) were determined by MTT(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay. These data suggest that some of these compounds provide good models for the further design of potent antitumor compounds. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=inorganic" title="inorganic">inorganic</a>, <a href="https://publications.waset.org/abstracts/search?q=uranyl%20complex-donor%20ligands" title=" uranyl complex-donor ligands"> uranyl complex-donor ligands</a>, <a href="https://publications.waset.org/abstracts/search?q=Schiff%20bases" title=" Schiff bases"> Schiff bases</a>, <a href="https://publications.waset.org/abstracts/search?q=anticancer%20activity" title=" anticancer activity"> anticancer activity</a> </p> <a href="https://publications.waset.org/abstracts/23527/synthesis-and-anti-cancer-evaluation-of-uranyle-complexes" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/23527.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">454</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">118</span> Breast Cancer as a Response to Distress in Women with or without a History of Precancerous Breast Disease</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Viacheslav%20Sushko">Viacheslav Sushko</a>, <a href="https://publications.waset.org/abstracts/search?q=Viktor%20Sushko"> Viktor Sushko</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Pre-cancerous breast diseases are pathological changes that precede the appearance of adenocarcinoma. The most common benign breast disease is mastopathy. We examined the life and disease history of 114 women aged 58-69 who were diagnosed with adenocarcinoma of the breast at different stages of development. They filled out the Reeder Scale to determine the level of stress. The results of the study revealed that 62 of them had mastopathy at the age of 30-45 years old. These women refused surgical treatment for mastopathy. Five to six years before their diagnosis of adenocarcinoma of the mammary gland, 84 women had experienced severe stress (death of a beloved close relative, torture accompanied by rape, prolonged stay in extreme conditions (under bombardment and bombardment). In the assessment of data from completed Reeder scales, 114 women had a high level of mental stress, with a score from 1-1.72. The 84 women who suffered from severe stress showed overeating or a significant decrease in food intake, insomnia, apathy, increased irritability and restlessness, loss of interest in sexual relationships, forgetfulness, difficulty in performing routine work, prolonged uncontrollable headaches, unexplained fatigue, heart pain, reduced capacity for work. In conclusion, it is important to provide psychotherapy for breast cancer patients as the diagnosis, and the different stages of treatment are very stressful. It is also advisable to see a psychiatrist at an early stage and prevent distress and treat precancerous breast disease. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=distress" title=" distress"> distress</a>, <a href="https://publications.waset.org/abstracts/search?q=mastopathy" title=" mastopathy"> mastopathy</a>, <a href="https://publications.waset.org/abstracts/search?q=severe%20stress" title=" severe stress"> severe stress</a> </p> <a href="https://publications.waset.org/abstracts/133809/breast-cancer-as-a-response-to-distress-in-women-with-or-without-a-history-of-precancerous-breast-disease" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/133809.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">135</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">117</span> Association of Mir-196a Expression in Esophageal Tissue with Barrett´s Esophagus and Esophageal Adenocarcinoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Petra%20Borilova%20Linhartova">Petra Borilova Linhartova</a>, <a href="https://publications.waset.org/abstracts/search?q=Michaela%20Ruckova"> Michaela Ruckova</a>, <a href="https://publications.waset.org/abstracts/search?q=Sabina%20Sevcikova"> Sabina Sevcikova</a>, <a href="https://publications.waset.org/abstracts/search?q=Natalie%20Mlcuchova"> Natalie Mlcuchova</a>, <a href="https://publications.waset.org/abstracts/search?q=Jan%20Bohm"> Jan Bohm</a>, <a href="https://publications.waset.org/abstracts/search?q=Katerina%20Zukalova"> Katerina Zukalova</a>, <a href="https://publications.waset.org/abstracts/search?q=Monika%20Vlachova"> Monika Vlachova</a>, <a href="https://publications.waset.org/abstracts/search?q=Jiri%20Dolina"> Jiri Dolina</a>, <a href="https://publications.waset.org/abstracts/search?q=Lumir%20Kunovsky"> Lumir Kunovsky</a>, <a href="https://publications.waset.org/abstracts/search?q=Radek%20Kroupa"> Radek Kroupa</a>, <a href="https://publications.waset.org/abstracts/search?q=Zdenek%20Pavlovsky"> Zdenek Pavlovsky</a>, <a href="https://publications.waset.org/abstracts/search?q=Zdenek%20Danek"> Zdenek Danek</a>, <a href="https://publications.waset.org/abstracts/search?q=Tereza%20Deissova"> Tereza Deissova</a>, <a href="https://publications.waset.org/abstracts/search?q=Lydie%20Izakovicova%20Holla"> Lydie Izakovicova Holla</a>, <a href="https://publications.waset.org/abstracts/search?q=Ondrej%20Slaby">Ondrej Slaby</a>, <a href="https://publications.waset.org/abstracts/search?q=Zdenek%20Kala"> Zdenek Kala</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Esophageal adenocarcinoma (EAC) is a highly aggressive malignancy that frequently develops from Barrett's esophagus (BE), a premalignant pathologic change occurring in the lower end of the esophagus. Specific microRNAs (miRNAs), small non-coding RNAs that function as posttranscriptional regulators of gene expression, were repeatedly proved to play key roles in the pathogenesis of these diseases. This pilot study aimed to analyze four selected miRNAs in esophageal tissues from healthy controls (HC) and patients with reflux esophagitis (RE)/BE/EAC, as well as to compare expression at the site of Barrett's mucosa/adenocarcinoma and healthy esophageal tissue outside the area of the main pathology in patients with BE/EAC. In this pilot study, 22 individuals (3 HC, 8 RE, 5 BE, 6 EAC) were included and endoscopically examined. RNA was isolated from the fresh-frozen esophageal tissue (stored in the RNAlater™ Stabilization Solution −70°C) using the AllPrep DNA/RNA/miRNA Universal Kit. Subsequent RT-qPCR analysis was performed using selected TaqMan MicroRNA Assays for miR-21, miR-34a, miR-196a, miR-196b, and endogenous control (RNU44). While the expression of miR-21 in the esophageal tissue with the main pathology was decreased in BE and EAC patients in comparison to the group of HC and RE patients (p=0.01), the expression of miR-196a was increased in the BE and EAC patients (p<0.01). Correlations between those miRNAs expression in tissue and severity of diagnosis were observed (p<0.05). In addition, miR-196a was significantly more expressed at the site with the main pathology than in paired adjacent esophageal tissue in BE and EAC patients (p<0.01). In conclusion, our pilot results showed that miR-196a, which regulates the proliferation, invasion, and migration (and was previously associated with esophageal squamous cell carcinoma and marked as a potential therapeutic target), could be a diagnostic tissue biomarker for BE and EAC as well. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=microRNA" title="microRNA">microRNA</a>, <a href="https://publications.waset.org/abstracts/search?q=barrett%C2%B4s%20esophagus" title=" barrett´s esophagus"> barrett´s esophagus</a>, <a href="https://publications.waset.org/abstracts/search?q=esophageal%20adenocarcinoma" title=" esophageal adenocarcinoma"> esophageal adenocarcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=biomarker" title=" biomarker"> biomarker</a> </p> <a href="https://publications.waset.org/abstracts/149454/association-of-mir-196a-expression-in-esophageal-tissue-with-barretts-esophagus-and-esophageal-adenocarcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/149454.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">112</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=rectal%20adenocarcinoma&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=rectal%20adenocarcinoma&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=rectal%20adenocarcinoma&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=rectal%20adenocarcinoma&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=rectal%20adenocarcinoma&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>